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Despite its longevity of use for anticoagulation during cardiac surgery, significant variability in heparin dos-ing and monitoring has been reported. A 1993 survey 
of members of the Society of Cardiovascular Anesthesiologists 
and American Society of Extracorporeal Technology demon-
strated that, although the activated clotting time was used 
by 99% of respondents, acceptable values for the conduct 
of cardiopulmonary bypass (CPB) ranged from 240 to 1000 
seconds.1 A survey of 54 North American institutions admin-
istered in 2008 by the Duke Clinical Research Institute and 
published by Lobato et al2 reported a similarly wide range of 
target activated clotting times, with values of 400–480 seconds 
being used by approximately 70% of respondents. Variability 
in anticoagulation practices is likely the result of a gap in evi-
dence and any formal recommendations. Only recently have 
the Society of Cardiovascular Anesthesiologists, American 
Society of Extracorporeal Technology, and the Society of 
Thoracic Surgeons released clinical practice guidelines for 
CPB anticoagulation.3
Decreased heparin responsiveness, frequently termed 
“heparin resistance,” is an area that lacks consensus in either 
diagnosis or treatment. The reported incidence during CPB 
use ranges from 4% to 26%4 and is highly dependent on the 
initial bolus dose of heparin and the desired activated clotting 
time target for CPB initiation. Therapies for heparin resistance 
include antithrombin concentrates, fresh frozen plasma, and 
the administration of additional heparin.4 The 2011 blood con-
servation guidelines from the Society of Thoracic Surgeons 
and Society of Cardiovascular Anesthesiologists recommend 
administration of antithrombin concentrates in preference to 
fresh frozen plasma in instances of antithrombin-mediated 
heparin resistance.5 However, the acceptance and impact of this 
recommendation remain unknown. In the report by Lobato et 
al,2 fresh frozen plasma was the predominant treatment for 
heparin resistance in 85% of US and Canadian centers.2
Recently, Miles et al6 conducted a global survey of CPB 
priming practices and reported that 72.7% of respondents 
used an activated clotting time target between 400 and 500 
seconds for initiation of CPB. That particular survey, how-
ever, asked only 1 question regarding activated clotting time 
values and contained no items related to heparin dosing or 
responsiveness. We conducted the present survey to describe 
both (1) current practice of anticoagulation for initiation and 
maintenance of CPB and (2) clinician attitudes on heparin 
resistance and their current use of antithrombin concentrates. 
In addition, since 2018 Society of Thoracic Surgeons/Society 
of Cardiovascular Anesthesiologists/American Society of 
Extracorporeal Technology CPB anticoagulation guidelines 
have just been released,3 we wanted to use the collected sur-
vey data to determine what percentage of practitioners are 
already compliant with these recommendations.
METHODS
Survey Creation and Validation
The authors used SurveyMonkey online software (San 
Mateo, CA) to create a pilot survey, which was admin-
istered to members of the Division of Cardiothoracic 
Anesthesiology at Emory University. Answers pertaining 
to heparin dosing and antithrombin concentrate usage were 
compared to known institutional protocols to ensure that the 
survey instrument was accurately capturing actual clinical 
practice. The final iteration of the survey had 20 questions 
and is provided in Supplemental Digital Content 1, Survey, 
We surveyed Society of Cardiovascular Anesthesiologists members regarding anticoagulation 
practices for cardiopulmonary bypass and attitudes on heparin resistance. Of 550 respondents 
(18.5% response rate), 74.9% (95% CI, 71.3%–78.5%) used empiric weight-based dosing of 
heparin, and 70.7% (95% CI, 66.9%–74.5%) targeted an activated clotting time of either 400 
or 480 seconds to initiate cardiopulmonary bypass. Of note, 17.1% (95% CI, 13.9%–20.2%) of 
respondents reported activated clotting time targets lower than those recommended by recent 
2018 Society of Thoracic Surgeons/Society of Cardiovascular Anesthesiologists/American 
Society of Extracorporeal Technology guidelines or failed to monitor heparin effects at all. When 
heparin resistance was encountered, 54.2% of respondents (95% CI, 50.0%–58.4%) adminis-
tered antithrombin concentrates as a first-line therapy.  (Anesth Analg 2019;129:e41–4)
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http://links.lww.com/AA/C680. The survey was reviewed 
and approved by the Society of Cardiovascular Anesthesio-
logists’s Research Committee and the Emory School of 
Medicine’s Institutional Review Board. The requirement for 
written informed consent was waived by both entities.
Survey Distribution
The target population was members of the Society of 
Cardiovascular Anesthesiologists at the “Active” and 
“Associate” levels, representing licensed physicians 
actively taking care of cardiac surgical patients. Members 
at the “Fellow/Resident” and “Career Scientist” levels were 
excluded. The Society of Cardiovascular Anesthesiologists 
membership office distributed an electronic link to the sur-
vey to all eligible members via an initial e-mail communi-
cation on August 2, 2017. Members had approximately 2 
months to complete the survey, with follow-up reminder 
e-mails sent on August 24, 2017 and September 29, 2017. 
The survey closed on October 1, 2017. Members were asked 
to complete the survey only once.
Determination of Guideline Compliance
The recent Society of Thoracic Surgeons/Society of 
Cardiovascular Anesthesiologists/American Society of 
Extracorporeal Technology guidelines for CPB anticoagu-
lation contain items related to “Heparin dosing for initia-
tion and maintenance of CPB.”3 The recommendations state 
that a clotting time should be measured and demonstrate 
“adequate anticoagulation” before initiation and at regular 
intervals during CPB.3 Guidance on minimal acceptable 
activated clotting time values is given as either >480 or 
>400 seconds when whole blood is maximally activated or 
microcuvette technology is used.3 Thus, respondents who 
either did not use activated clotting times or targeted acti-
vated clotting times <400 seconds either before initiation of 
CPB or during CPB (survey questions 8, 9, and 11) were con-
sidered not compliant with these recommendations.
Completion Incentive
Responses were anonymous, but participants had the 
option of entering an e-mail address into a random draw-
ing for 1 of 10 Amazon gift cards valued at $125 and 1 of 
5 annual memberships to the Society of Cardiovascular 
Anesthesiologists (value of $270).
Responses Analyzed
Respondents who indicated on the survey that they did 
not care for adult patients undergoing cardiac surgery 
using CPB were excluded. Responses with identical e-mail 
addresses entered for the incentive drawing were consid-
ered to be duplicates, and only the first completed survey 
was used for purposes of the incentive drawing and the 
analysis. Respondents who entered only demographic 
information for the purposes of the incentive drawing were 
not used in the analysis.
Statistical Analysis
Based on an estimated membership population of 3000, CIs 
of 95%, and a sample proportion of 0.5, we calculated that 
we would need 501 responses to achieve a global margin 
of error of 4%. Descriptive statistics, including frequency 
tables with proportions and bar graphs, were used to sum-
marize the data. Wald CIs for proportions were set at 95%. 
Responses to individual questions that were left blank were 
classified as “unknown.” All calculations were performed 
using SAS software version 9.4 (SAS Institute Inc, Cary, NC).
RESULTS
The electronic link to the survey was distributed to 2972 
Society of Cardiovascular Anesthesiologists members. 
We received 580 responses, of which 550 were used 
for analysis, giving an effective response rate of 18.5% 
(Supplemental Digital Content 2, Figure 2, http://links.
lww.com/AA/C681). Respondent demographics are 
provided in the Table and closely mirrored the mem-
bership composition of the Society of Cardiovascular 
Anesthesiologists (Supplemental Digital Content 3, Figure 
3A, http://links.lww.com/AA/C682), with 83.8% of 
responses coming from North America. Responses from 
all states within the United States were received, with 
the exceptions of Delaware, Idaho, North Dakota, South 
Dakota, and Wyoming (Supplemental Digital Content 3, 
Figure 3B, http://links.lww.com/AA/C682).
Answers to specific heparin management questions are 
provided in the Table. An empiric weight-based approach to 
determining the pre-CPB heparin bolus was used by 74.9% of 
respondents (95% CI, 71.3%–78.5%). Empiric weight-based 
doses of heparin used for initiation of CPB are provided 
in Figure  1A. The maximum dose of heparin that respon-
dents would administer before initiating additional ther-
apy to achieve a target activated clotting time is provided 
in Figure 1B. Heparin was also added to the CPB circuit by 
the majority of respondents (84%; 95% CI, 80.9%–87.0%). 
Adequate anticoagulation was assessed by targeting a spe-
cific activated clotting time for “initiation” of CPB and “dur-
ing” CPB by 84.7% (95% CI, 81.7%–87.7%) and 88.4% (95% 
CI, 85.7%–91.1%) of respondents, respectively. In addition to 
an activated clotting time, 13.1% (95% CI, 10.3%–15.9%) also 
used a heparin level to determine adequate anticoagulation 
for initiation of CPB, and 6.7% (95% CI, 4.6%–8.8%) main-
tained a specific heparin level during CPB.
For those respondents who used an activated clotting 
time to determine adequate anticoagulation for CPB initia-
tion, either with or without a heparin level (538 of 550), an 
activated clotting time value of 480 or 400 seconds was used 
by 70.7% (95% CI, 66.9%–74.5%). The full range of activated 
clotting time targets for initiation and maintenance of CPB 
is provided in Figure 2. Of the 550 respondents, 17.1% (95% 
CI, 13.9%–20.2%) provided answers inconsistent with 2018 
Society of Thoracic Surgeons/Society of Cardiovascular 
Anesthesiologists/American Society of Extracorporeal 
Technology guidelines regarding activated clotting time 
targets for initiation and/or maintenance of CPB.
Specific answers to questions regarding heparin resis-
tance are provided in the Table. In terms of frequency, 
about half of respondents felt that they encountered it in 
1%–10% of the CPB cases they performed. More clinicians 
administered antithrombin concentrate as a first-line treat-
ment (54.2%; 95% CI, 50.0%–58.5%) compared to those who 
administered fresh frozen plasma as a first-line treatment 
Society of Cardiovascular Anesthesiologists Anticoagulation Survey
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(38.4%; 95% CI, 34.3%–42.4%). The majority of respon-
dents were in agreement with the 2011 Society of Thoracic 
Surgeons/Society of Cardiovascular Anesthesiologists rec-
ommendation to use antithrombin concentrate, although 
about one-third rarely or never utilized it in cases of hepa-
rin resistance. The primary reason antithrombin concen-
trates were not used in this situation was cost being too 
high and antithrombin concentrates not being on the hos-
pital formulary.
DISCUSSION
Our survey of Society of Cardiovascular Anesthesiologists 
members regarding anticoagulation practices for CPB con-
sisted mostly of clinicians in North America but included 
a balanced distribution of small-, medium-, and large-vol-
ume centers, as well as a close split between programs with 
and without trainees. Like the survey conducted in 2008 
by Lobato et al,2 we found that empiric dosing of heparin 
with activated clotting time targets of 400 or 480 seconds 
is used by the majority of practitioners. Of note, however, 
is that >15% of respondents reported using anticoagulation 
therapy falling outside of recent 2018 Society of Thoracic 
Surgeons/Society of Cardiovascular Anesthesiologists/
American Society of Extracorporeal Technology guidelines3; 
it may be useful to use this number as a starting point to 
gauge adoption of these recommendations. It is also inter-
esting to note that more clinicians now use antithrombin 
When you encounter heparin resistance, 
how often do you administer 
antithrombin concentrate?
Always/very often 220 (40.0) 35.9%–44.1%
Often/sometimes 112 (20.4) 17.0%–23.7%
Rarely/never 192 (34.9) 30.9%–38.9%
Unknown 26 (4.7) 2.9%–6.5%
Do you agree with the 2011 Society 
of Thoracic Surgeons/Society of 
Cardiovascular Anesthesiologists 
Blood Conservation recommendation 
regarding use of antithrombin 
concentrate to treat heparin 
resistance?
Yes 283 (51.5) 47.3%–55.6%
Yes, but not as a class I 
recommendation
89 (16.2) 13.1%–19.3%
No 7 (1.3) 0.3%–2.2%
I am not familiar with this 
recommendation
145 (26.4) 22.7%–30.1%
Unknown 26 (4.7) 2.9%–6.5%
When antithrombin concentrate is not 
used in cases of heparin resistance, 
the primary reason is:
Not on my hospital’s formulary 76 (32.5) 26.4%–38.5%
The cost is too high 74 (31.6) 25.6%–37.6%
I prefer to give fresh frozen plasma 44 (18.8) 13.8%–23.8%
Unfamiliar with antithrombin 
concentrate or recommendations
40 (17.1) 12.2%–22.0%
Results are given as n (%) of respondents selecting a particular answer.
Abbreviation: CPB, cardiopulmonary bypass.
Table.  Continued
Attitudes on Heparin Resistance n (%) 95% CI of %
Table.  Survey Responses
Demographics of Respondents n (%)
Region  
United States 430 (78.2)
Canada 31 (5.6)
Europe 34 (6.2)
Australia/New Zealand 26 (4.7)
Mexico/South America 17 (3.1)
Asia 11 (2.0)
Africa/Middle East 1 (0.2)
Do you work with anesthesia residents  
of fellows? (“Yes” response)
332 (60.4)
No. of CPB cases per year  
≤250 107 (19.5)
251–500 152 (27.6)
501–1000 172 (31.3)
>1000 119 (21.6)
Heparin Management n (%) 95% CI of %
How do you determine the dose of 
heparin to administer before  
initiating CPB?
Empiric weight based (eg, units/kg) 412 (74.9) 71.3%–78.5%
Dose–response calculation (eg, Hepcon 
[Medtronic, Minneapolis, MN])
135 (24.5) 20.9%–28.1%
Other/unknown 3 (0.5) 0%–1.2%
How do you determine an adequate 
degree of anticoagulation for 
initiation of CPB?
Target an activated clotting time 466 (84.7) 81.7%–87.7%
Target both an activated clotting time 
and heparin level
72 (13.1) 10.3%–15.9%
Other 8 (1.5) 0.5%–2.5%
Unknown 4 (0.7) 0%–1.4%
Do you add heparin to the CPB circuit/ 
reservoir before initiating CPB?
  
Yes 462 (84) 80.9%–87.0%
No 71 (12.9) 10.1%–15.7%
Unknown 17 (3.1) 1.6%–4.5%
How do you maintain anticoagulation 
during CPB (ie, after CPB is already 
initiated)?
Give additional heparin to target an 
activated clotting time
486 (88.4) 85.7%–91.1%
Give additional heparin to maintain 
heparin level
37 (6.7) 4.6%–8.8%
Other 20 (3.6) 2.1%–5.2%
Unknown 7 (1.3) 0.3%–2.2%
Attitudes on Heparin Resistance n (%) 95% CI of %
Approximately what percentage of cardiac 
surgical cases using CPB do you 
encounter clinically significant 
heparin resistance?
<1% 191 (34.7) 30.7%–38.7%
1%–10% 298 (54.2) 50.0%–58.4%
>10% 47 (8.5) 6.2%–10.9%
Unknown 14 (2.5) 1.2%–3.9%
Assuming the desired level of 
anticoagulation is not achieved with 
heparin alone, what is the first action 
you would take?
Administer antithrombin concentrate 298 (54.2) 50.0%–58.4%
Administer fresh frozen plasma 211 (38.4) 34.3%–42.4%
Administer an alternate anticoagulant 12 (2.2) 1.0%–3.4%
Initiate CPB anyway 5 (0.9) 0.1%–1.7%
Unknown 24 (4.4) 2.7%–6.1%
(Continued)
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concentrate in cases of heparin resistance compared to 10 
years ago. In conclusion, while anticoagulation targets for 
CPB, as determined by the activated clotting time, have 
remained steady over the past decade, antithrombin con-
centrate utilization has increased when those targets are felt 
to be inadequately met. E 
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Figure 1. Bar graphs of (A) percentage 
of respondents indicating either empiric 
weight-based dose or a calculated dose 
based on heparin dose–response (HDR) 
curve, which is typically administered 
before the initiation of cardiopulmonary 
bypass (CPB), and (B) percentage of 
respondents indicating what the maxi-
mum dose of heparin they would give 
before administering additional therapy 
to achieve the desired level of antico-
agulation for CPB. Doses are given in 
U/kg. Error bars indicate Wald 95% CIs 
of the proportion.
Figure 2. Bar graph of percentage of those respondents who utilized 
activated clotting times (ACTs) targeting a specific ACT value for ini-
tiation (green bars) and maintenance (red bars) of cardiopulmonary 
bypass (CPB). Error bars indicate Wald 95% CIs of the proportion.
